WOOJUNG BIO, Inc. announced that it expects to receive KRW 2.5 billion in funding from Mirae Asset Daewoo Co., Ltd., Investment Arm, Focus Investment Co., Ltd.
August 08, 2018
Share
WOOJUNG BIO, Inc. (KOSDAQ:A215380) announced a private placement of 5th series unregistered unsecured coupon unguaranteed private convertible bond for gross proceeds of KRW 2,500,000,000 on August 8, 2018. The transaction will include participation from existing investor, Mirae Asset Daewoo Co., Ltd., Investment Arm. The bonds carry no coupon and yield to maturity. The bond would mature on August 10, 2023. The bonds are convertible into common shares of the company at a conversion price of KRW 2,993 per share. The conversion will start on August 10, 2019 and end on July 10, 2023. The transaction is expected to close on August 10, 2018. The transaction has been approved by the board of directors of the company.
Woojung Bio Inc is a Korea-based company principally engaged in the biological business. The Company operates its business through two segments. The Infection Control Business segment is engaged in the manufacture and sale of reagents, breeding equipment, hydrogen peroxide sterilizers and other products. The Biological Business segment is engaged in the provision of test agency, research service and passage management services.
WOOJUNG BIO, Inc. announced that it expects to receive KRW 2.5 billion in funding from Mirae Asset Daewoo Co., Ltd., Investment Arm, Focus Investment Co., Ltd.
WOOJUNG BIO, INC. 
